Doctor and patient
 

Our strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.

Approach

Benefit
Pursue multiple programmes
  • Increase potential success rate
  • Mitigate development risk
Seek collaboration partners
  • Spread financial cost and risk
  • Introduce specialist research expertise

Develop programmes to pre-clinical/
early clinical development
  • Minimise ongoing development risk
  • Move up value chain
  • Potential for higher deal values

  • @Sareumplc Latest tweet

    RT @HybridanLLP: Good to see Sareum's research on TYK2 as an oncology target referenced here. We see Sareum as a frontrunner in this space… via @Sareumplc
    View more

Contact

Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom


tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
email_white.png

Downloads

Full-year Results 2020 ¦ Brochure Jan 2021

Annual Report 2020     ¦

Annual Report 2020      Brochure